Papers/PMID:39234246
Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: a randomized, double-blind, placebo-controlled trial.
Frontiers in immunology2024The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
Lacticaseibacillus rhamnosus — no detected effect on helicobacter pylori eradication rate
Evidence strength: moderate.FindingNull result“The LRa05 group had a higher eradication rate than the placebo group (B), but there was no significant difference in the eradication rate between the two groups (Chi square = 0.144, p = 0.7048).”
Quoted verbatim from Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: a randomized, double-blind, placebo-controlled trial.. - Study
- RCT
- Duration
- 4 weeks
- Dose
- 1 x 10^10 CFU per day, 3 g packet, for four weeks (first two weeks with antibiotics)
- Population
- Adults with H. pylori infection receiving rabeprazole, levofloxacin, metronidazole and bismuth pectin in both arms; 36 in the LRa05 arm and 35 on placebo analysed
Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: a randomized, double-blind, placebo-controlled trial.2024PMID:3923424610.3389/fimmu.2024.1450414Permalink